Genetic variation in nitric oxide production may influence outcomes in patients with heart failure and reduced ejection fraction (HFrEF)..

A cross-sectional descriptive study published in Open Cardiovascular Medicine Journal investigated the association between the –786T/C (rs2070744) polymorphism in the NOS3 gene and cardiovascular outcomes in patients with (HFrEF). The study included 90 patients at Bac Lieu General Hospital, Vietnam, from April 2023 to June 2024. Genotyping was performed using RFLP-PCR, and patients were followed for 3 and 6 months to assess heart failure-related readmission and mortality.

Genotype distribution was TT (61.1%), CT (32.2%), and CC (6.7%). At 3 months, 32.2% of patients were readmitted and 10.0% died; at 6 months, readmission was 25.9% and mortality 8.6%. The CC genotype was significantly associated with higher readmission and mortality at 3 months. Multivariate Cox regression identified CC/CT genotype (HR 4.24; 95% CI 1.03–17.39; p<0.05) and dyslipidemia (HR 8.63; 95% CI 2.12–41.03; p<0.05) as independent predictors of mortality.

The findings suggest that the rs2070744 polymorphism in NOS3 may serve as a prognostic biomarker for poor outcomes in HFrEF. CC/CT genotype carriers and patients with dyslipidemia appear to be at increased risk of readmission and death.